Do pulmonary findings of granulomatosis with polyangiitis respond to anti-tuberculosis treatment?

  • Döndü Üsküdar Cansu
  • Nilgün Işıksalan Özbülbül
  • Gülsüm Akyol
  • Deniz Arık
  • Cengiz Korkmaz
Cases with a Message


Granulomatosis with polyangiitis (GPA) involves upper and lower respiratory tracts and kidneys. Lung involvement is among the most important organ involvements in GPA. GPA’s lung involvement might be confused with other granulomatous conditions with lung involvement. In this report, we presented clinical features of two cases with GPA who had been diagnosed as tuberculosis (TBC) and well treated with anti-tuberculosis (anti-TBC) drugs. However, one of two cases had ear–nose–throat (ENT) manifestations before the diagnosis of TBC and her extrapulmonary findings related with GPA have added to clinical features in the following years. In the second case, the manifestations of GPA appeared after 13 months of anti-TBC treatment. We speculated that lung involvement in these cases may be due to GPA rather than TBC. Our aim was to highlight difficulties in the differential diagnosis between GPA and TBC and suggest the possible beneficial effect of anti-TBC drugs on the lung involvement due to GPA in light of the literature data.


Wegener granulomatosis Granulomatosis with polyangiitis Tuberculosis Anti-tuberculosis treatment 


Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from our patients.


  1. 1.
    Calabrese LH, Molloy ES, Duna G (2009) Antineutrophilic cytoplasmic antibody-associated vasculitis. In: Firestein GS, Budd EC, Harris ED, Mc Innes IB, Ruddy S, Sergent JS (eds) Kelley’s textbook, 8th edn. Elsevier, Philadelphia, pp 1429–1451Google Scholar
  2. 2.
    Toyoshima M, Chida K, Suda T, Imokawa S, Nakamura H (2001) Wegener’s granulomatosis responding to antituberculous drugs. Chest 119:643–645CrossRefPubMedGoogle Scholar
  3. 3.
    Khilnani GC, Banga A, Sharma SC, Gupta SD (2003) Wegener’s granulomatosis: an isolated lung mass responding to antituberculosis therapy and atypical course. J Assoc Phys India 51:731–733Google Scholar
  4. 4.
    Izzedine H, Servais A, Launay-Vacher V, Deray G (2002) Retroperitoneal fibrosis due to Wegener’s granulomatosis: a misdiagnosis as tuberculosis. Am J Med 113:164–166CrossRefPubMedGoogle Scholar
  5. 5.
    Breuskin F, Polet MA, Dorzee J, Fastrez J, Van Eeckhout P, Henkinbrant A, d’Odemont JP (2003) Limited Wegener’s disease initially misdiagnosed as tuberculosis. Acta Clin Belg 58:245–247CrossRefPubMedGoogle Scholar
  6. 6.
    Flores-Suárez LF, Saldarriaga Rivera LM, Rivera Rosales RM, Ruiz N, Báez Saldaña R (2015) Cavitary tuberculosis and tracheal stenosis simulating granulomatosis with polyangiitis. Int J Tuberc Lung Dis 19:369–370CrossRefPubMedGoogle Scholar
  7. 7.
    Mahmood FS, Schwatz E, Kurrup S, Sharp C, Hands G, Moody A (2013) A diagnostic dilemma: differentiating between granulomatosis with polyangiitis and tuberculosis. Clin Med (Lond) 13:411–413CrossRefGoogle Scholar
  8. 8.
    Gordon C, Luqmani R, Fields P, Howie AJ, Emery P (1993) Two cases of ‘Wegener’s tuberculosis’. Br J Rheumatol 32:143–149CrossRefPubMedGoogle Scholar
  9. 9.
    Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG (1996) Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335:16–20CrossRefPubMedGoogle Scholar
  10. 10.
    Hayashi H, Morimoto K, Nakazawa K, Fujita J, Mori T, Sunada K, Watanabe K, Hayashihara K, Saito T, Kawabata Y (2007) A case of limited form of Wegener’s granulomatosis showing repeated occurrence and disappearance of nodules in chest X ray with no medication. Nihon Kokyuki Gakkai Zasshi 45:726–730PubMedGoogle Scholar
  11. 11.
    Inoue K, Kawahito Y, Sano H, Yoshikawa T (2001) Antituberculous drugs for Wegener’s granulomatosis. Chest 120:2112–2113CrossRefPubMedGoogle Scholar
  12. 12.
    Nilsson BS (1971). Rifampicin: an immunosuppressant? Lancet 2:p 374Google Scholar
  13. 13.
    Gupta S, Grieco MH, Siegel I (1975) Suppression of T-lymphocyte rosettes by rifampin. Studies in normals and patients with tuberculosis. Ann Intern Med 82:484–488CrossRefPubMedGoogle Scholar
  14. 14.
    Ziglam HM, Daniels I, Finch RG (2004) Immunomodulating activity of rifampicin. J Chemother 16:357–361CrossRefPubMedGoogle Scholar
  15. 15.
    Galal SH, Khalil SH, el Husseiny W, Brock J (1988) Cell mediated and humoral immunity and light-chain proteinuria in rifampicin-treated tuberculous patients. Allerg Immunol (Leipz) 34:249–254Google Scholar
  16. 16.
    Tsankov N, Grozdev I (2011) Rifampicin–a mild immunosuppressive agent for psoriasis. J Dermatolog Treat 22:62–64CrossRefPubMedGoogle Scholar
  17. 17.
    Kim PK, Kim KS, Lee JK, Lee JS, Jeong HJ, Choi IJ (1988) Rifampin therapy in Henoch-Schönlein purpura nephritis accompanied by nephrotic syndrome. Child Nephrol Urol 9:50–56PubMedGoogle Scholar
  18. 18.
    Pajor AM, Józefowicz-Korczyńska M, Korzeniewska-Koseła M, Kwiatkowska S (2016) A clinic-epidemiological study of head and neck tuberculosis—a single-center experience. Adv Respir Med 84:324–330CrossRefPubMedGoogle Scholar
  19. 19.
    Menon K, Bem C, Gouldesbrough D, Strachan DR (2007) A clinical review of 128 cases of head and neck tuberculosis presenting over a 10-year period in Bradford, UK. J Laryngol Otol 121:362–368CrossRefPubMedGoogle Scholar
  20. 20.
    Sawada N, Inokuchi G, Komatsu H, Kurakawa S, Tada K, Kumoi K (2013) Nasopharyngeal tuberculosis. J Infect Chemother 19:1158–1160CrossRefPubMedGoogle Scholar
  21. 21.
    Rueda JC, Crepy MF, Mantilla RD (2013) Clinical features of Poncet’s disease. From the description of 198 cases found in the literature. Clin Rheumatol 32:929–935CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Rheumatology, Department of Internal Medicine, School of MedicineEskişehir Osmangazi UniversityEskisehirTurkey
  2. 2.Department of RadiologyEskişehir Osmangazi UniversityEskisehirTurkey
  3. 3.Department of Internal MedicineEskişehir Osmangazi UniversityEskisehirTurkey
  4. 4.Division of PathologyEskişehir Osmangazi UniversityEskisehirTurkey

Personalised recommendations